Reduced H3K27me3 levels in diffuse gliomas: association with 1p/19q codeletion and difference from H3K27me3 loss in mali
- PDF / 1,419,806 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 118 Downloads / 155 Views
ORIGINAL ARTICLE
Reduced H3K27me3 levels in diffuse gliomas: association with 1p/19q codeletion and difference from H3K27me3 loss in malignant peripheral nerve sheath tumors Keiichiro Kitahama1 · Shohei Iijima2 · Ayumi Sumiishi1 · Akimasa Hayashi1 · Kiyotaka Nagahama1 · Kuniaki Saito2 · Nobuyoshi Sasaki2 · Keiichi Kobayashi2 · Saki Shimizu2 · Motoo Nagane2 · Junji Shibahara1 Received: 21 August 2020 / Accepted: 17 September 2020 © The Japan Society of Brain Tumor Pathology 2020
Abstract Trimethylation of histone H3 at lysine 27 (H3K27me3) acts as a transcriptional repressor of target genes. Recent immunohistochemical studies have reported a loss of H3K27me3 modification in diffuse (especially 1p/19q-codeleted) gliomas. However, we did not observe H3K27me3 loss in diffuse gliomas using routine immunostaining conditions for the detection of H3K27me3 loss in malignant peripheral nerve sheath tumors (MPNSTs). Therefore, we conducted immunohistochemical analysis of surgically resected specimens to understand the differences in the H3K27me3 status in MPNSTs and diffuse gliomas and evaluate the diagnostic utility of H3K27me3 immunohistochemistry. Staining with a standard 1:200 dilution of the C36B11 antibody showed a complete loss of H3K27me3 in 5 out of 11 MPNSTs, whereas most diffuse gliomas (149/151, 98.7%) showed diffuse immunoreactivity. At a 1:2000 antibody dilution, 12.6% (19/151) of the diffuse gliomas showed H3K27me3 loss, which was significantly associated with 1p/19q codeletion (P
Data Loading...
